Search

Your search keyword '"Bruzzone, B."' showing total 427 results

Search Constraints

Start Over You searched for: Author "Bruzzone, B." Remove constraint Author: "Bruzzone, B."
427 results on '"Bruzzone, B."'

Search Results

5. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

6. Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021

7. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

10. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

11. Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study

12. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

16. Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021

17. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

18. Determinants of SARS-CoV-2 infection in Italian healthcare workers: a multicenter study

19. A Comparison of Hepatitis B Seroepidemiology in Ten European Countries

20. The European Sero-Epidemiology Network 2 (ESEN2): Standardization of Assay Results for Hepatitis A Virus (HAV) to Enable Comparisons of Seroprevalence Data across 15 Countries

22. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group

23. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

24. Detection of influenza A(H1N1)pdm09 virus in a patient travelling from Shanghai to Italy in July 2018: an uncommon clinical presentation in a non-seasonal period

25. Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity

26. Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database

27. Marked decrease in acquired resistance to antiretrovirals in latest years in Italy

28. 2287P Multiomic Biological mOdifications in the immune response of patients treated with chemotherapy, anti-CD20, or immune-checkpoint inhibitors and receiving a Third dose of vaccinE against SARS-CoV-2 (the BO0STER study)

29. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

31. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

32. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

33. Dar voce alla differenza: un compito per l'educazione

34. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

35. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

36. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

39. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

42. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

43. Surveillance and prevention of viral hepatitis A and B in Europe: lessons learnt and considerations for the future: Workshop: The comparative sero-epidemiology of Hepatitis A and B in 14 countries participating in the European Sero-Epidemiology Network (ESEN2)

45. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

46. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

47. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

48. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

49. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

50. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

Catalog

Books, media, physical & digital resources